Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
Galapagos NV
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
TORL Biotherapeutics, LLC
Lyell Immunopharma, Inc.
AstraZeneca
M.D. Anderson Cancer Center
Instituto de Investigación Biomédica de Salamanca
National Research Center for Hematology, Russia
Merck Sharp & Dohme LLC
AstraZeneca
Suzhou Immunofoco Biotechnology Co., Ltd
Eli Lilly and Company
National University Hospital, Singapore
Fred Hutchinson Cancer Center
CRISPR Therapeutics
AVM Biotechnology Inc
CRISPR Therapeutics
M.D. Anderson Cancer Center
Gilead Sciences
Barbara Ann Karmanos Cancer Institute
Chinese PLA General Hospital
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Estrella Immunopharma, Inc.
Essen Biotech
Shenzhen University General Hospital
National Institutes of Health Clinical Center (CC)
Cancer Research UK
CRISPR Therapeutics
Chinese PLA General Hospital
Shanghai Tongji Hospital, Tongji University School of Medicine
University of Pittsburgh
Novartis
Step Pharma, SAS
Gamida Cell ltd
M.D. Anderson Cancer Center
Dizal Pharmaceuticals
Affiliated Hospital to Academy of Military Medical Sciences
Genmab
Hoffmann-La Roche
Oncternal Therapeutics, Inc
Hoffmann-La Roche
Miltenyi Biomedicine GmbH
MingSight Pharmaceuticals, Inc
Fred Hutchinson Cancer Center
Academic and Community Cancer Research United
Uppsala University